Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Trial of Active Surveillance Versus Continued Systemic Immunotherapy After Achieving Tumor-Free Status in Extensive Transurethrally Unresectable Very-High-Risk NMIBC

NCT07625527 is registered in ClinicalTrials.gov with Tianjin Medical University Second Hospital as lead sponsor.

NCT NCT07625527
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07625527 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Trial of Active Surveillance Versus Continued Systemic Immunotherapy After Achieving Tumor-Free Status in Extensive Transurethrally Unresectable Very-High-Risk NMIBC
Lead sponsor
Tianjin Medical University Second Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 30, 2026
Completion date
May 30, 2032
Enrollment
120 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

bladder (urothelial, transitional cell) cancer, non muscle invasive bladder cancer